PT  - JOURNAL ARTICLE
AU  - Asem, Noha
AU  - Massoud, Hossam Hosny
AU  - Serag, Ihab
AU  - Hassany, Mohamed
AU  - ElAssal, Gehan
AU  - Abdelbary, Akram
AU  - Mohsen, Marwa
AU  - Baki, Amin Abdel
AU  - Zaky, Samy
AU  - Amin, Wagdy
AU  - Kamal, Ehab
AU  - Ibrahem, Hamdy
AU  - Abdel Mohsen, Ahmed Said
AU  - Ali, Mohamed Ahmed
AU  - Elgendy, Nancy
AU  - Elbadry, Mohamed
AU  - Ahmed, Salwa Hassan
AU  - shenouda, Ahmed Naguib Nassif
AU  - Fathy, Mohamed Abdelhamed
AU  - Zaid, Hala
TI  - Clinical efficacy of Early Administration of Convalescent Plasma among COVID-19 Cases in Egypt
AID  - 10.1101/2021.03.30.21254031
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.30.21254031
4099  - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254031.short
4100  - http://medrxiv.org/content/early/2021/04/04/2021.03.30.21254031.full
AB  - Importance Early and effective treatment of COVID-19 is vital for control of SARS-CoV-2 infectionObjectives The primary objective of the study was to assess the degree of clinical improvement in severe and critically ill COVID-19 patients, treated early with early CPT.Designs An interventional, single-arm, non-randomized clinical trial conducted in Egypt from April 15 to July 21, 2020.Settings This was a multi-centre study conducted in 3 hospitals in Egypt.Participants a total of 94 COVID-19 laboratory-confirmed patients using qRT-PCR were enrolled in the study.Intervention All patients were administered with two plasma units (each unit is 200cc). The volume of donated plasma was 800cc.Main Outcome and Measures Primary measure was the degree of clinical improvement among the COVID-19 patients who received CPT within seven daysResults A total of 94 patients were enrolled who received CPT either within seven days or after seven days of hospitalization. 82 were severely ill, 12 were critically ill. The average age remained 58 years (±SD 15.1 years). Male were 69% and 49% patients got cured while 51% died with CFR 51%. 75% deaths were above 45years of age. The symptoms were dyspnoea (55%), fever (52%), cough (46%), and loss of taste and smell (21%), and cyanosis (15%). The most common co-morbidities among the <40 years remained Diabetes Mellitus (21%) and Asthma (14%). Among 40-60 years Hypertension (56%), Diabetes Mellitus (39%) and among >60 years age group Hypertension (57%) and Chronic Heart Disease (24%) were reported. CPT within seven days remained significant as compared with the CPT after seven days with the number of days to cure (p=0.007) and ICU stay (P=0.008) among severely ill cured cases.Conclusion and Relevance Among patients with COVID-19 and severe or critical illness, the use of CPT along with routine standard therapy resulted in a statistically significant improvement when administered within seven days of hospital admission. However, plasma transfusion, irrespective of days to transfusion may not help treat critically ill patients. The overall mean time to cure in severely ill patients was 15 days if CPT provided within seven days with 65% cure rate.Trial Registration Clinical Intervention identifier: MOHP_COVID-19_Ver1.1Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04816942Funding StatementMinistry of health and populationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ministry of Health and Population Ethics Committees (MOHP-EC) and was registered in Egypt no. MOHP_COVID-19_Ver1.1.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are available